MRG002-HER2low

NCT04492488 📎

Regimen

Experimental
MRG002 (trastuzumab-MMAE ADC) 2.6 mg/kg IV q3w (single-arm phase 2 expansion).
Control
N/A (single-arm)

Population

HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer previously treated with chemotherapy; HR+ subgroup required progression on endocrine therapy.

Key finding

MRG002 (Shanghai Miracogen trastuzumab-MMAE ADC) showed clinically meaningful activity in HER2-low MBC. Distinct from T-DXd payload (DXd topoisomerase I inhibitor) -- MMAE tubulin payload makes it a mechanistically different Chinese HER2 ADC entry.

Timeline

    Guideline citations

    • NCCN BREAST